TY -的T1 -匹兹堡化合物b PET和MRI生物标志物的认知老化医学患者(P4.347) JF -神经学乔-神经学六世- 88 - 16补充SP - P4.347盟Burcu Zeydan AU - Val j·首页劳盟斯科特·a·Przybelski AU -克里斯托弗·g·施瓦兹盟Nirubol Tosakulwong盟——萨曼塔·m·祖克盟——马修·l·Senjem AU -杰弗瑞·l·冈特盟玫瑰花蕾o·罗伯茨AU -米歇尔·m·Mielke盟爱德华多·e·Benarroch盟摩西·罗德里格斯AU -玛丽·m·Machulda盟Timothy g . Lesnick盟——David s . Knopman盟——罗纳德·c·彼得森AU -克利福德·r·杰克,小非盟- Kejal Kantarci AU - Orhun h . Kantarci Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P4.347.abstract N2 -目的:我们研究协会的认知功能与丘脑的体积,大叶性大脑皮层厚度、c[11]匹兹堡化合物b(加以)正电子发射断层扫描(PET)和白质(WM)作为一个潜在的髓鞘加以结合标记在女士的人口老龄化。背景:先进的核磁共振成像技术用于成像髓不myelin-specific脑实质。相比之下,淀粉体示踪剂等加以最近显示目标髓;宠物可能候选人形象脱髓鞘疾病。设计/方法:以人群为基础的梅奥诊所的研究衰老,24女士4869参与者,与一个子集进行了大脑核磁共振(n = 16)和PiB-PET (n = 12)。一个女士轻度认知障碍患者完成标准而另一个痴呆和PiB-PET既不会满足标准。控制从同一队列是年龄,sex-matched女士(5:1)的病人。定量图像分析使用自动或半自动图像处理管道。结果:医学患者认知记忆的z得分较低(p = 0.03)和语言比控制(p = 0.02)。MS患者小丘脑卷(p = 0.003),薄(p = 0.001)和颞皮层薄额叶皮层比控制(p = 0.045)。丘脑的体积损失与注意力执行性能下降(p = 0.02)。 PiB uptake was reduced in areas of WM hyperintensities compared to normal appearing WM in MS (p=0.0002) and controls (p<0.0001). Reduced PiB uptake in areas of WM hyperintensities was associated with decreased visuospatial performance in MS (p=0.02). There was no difference in global cortical PiB standardized uptake value ratios between MS and controls (p=0.39).Conclusions: Thalamic atrophy correlates with lower attention-executive function in late MS and likely reflects WM injury in thalamo-cortical projections. PiB-PET as a potential measure of WM injury, correlates with visuospatial processing and may reflect injury to association area connectivity.Study Supported by: This study was funded by the NIH [R01 AG040042, P50 AG016574, U01 AG006786, C06 RR018898], The Minnesota Partnership for Biotechnology and Medical Genomics, The Elsie and Marvin Dekelboum Family Foundation and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program.Disclosure: Dr. Zeydan has nothing to disclose. Dr. Lowe received personal compensation for activities with Bayer Pharmaceuticals as a consultant. Dr. Przybelski has nothing to disclose. Dr. Schwarz has nothing to disclose. Dr. Tosakulwong has nothing to disclose. Dr. Zuk has nothing to disclose. Dr. Senjem has nothing to disclose. Dr. Gunter has nothing to disclose. Dr. Roberts has nothing to disclose. Dr. Mielke has received personal compensation for activities with Lysosomal Therapeutics, Inc. as a consultant. Dr. Mielke has received research support from Biogen. Dr. Benarroch has received personal compensation in an editorial capacity for being a section editor for Neurology. Dr. Rodriguez has received research support from Acorda Therapeutics, Inc. Dr. Machulda has nothing to disclose. Dr. Lesnick has nothing to disclose. Dr. Knopman has received personal compensation for activities with Lundbeck Pharmaceuticals.Dr. Knopman has received research support from Lilly Pharmaceuticals, Biogen and TauRX. Dr. Petersen received personal compensation for activities with Merck, Roche, Genentech, Biogen, and Eli Lilly and Co. Dr. Jack has received personal compensation for activities with Janssen Research & Development, LLC by providing consulting services. Dr. Jack has received research support from the National Institutes of Health (R01-AG011378, RO1-AG041851, RO1-AG037551. Dr. Katarci has received royalty payments from Takeda. Dr. Kantarci has nothing to disclose. ER -